このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Aurobindo Pharma 過去の業績
過去 基準チェック /46
Aurobindo Pharmaの収益は年間平均-4.6%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間17% 4.9%割合で 増加しています。 Aurobindo Pharmaの自己資本利益率は10.6%であり、純利益率は10.9%です。
主要情報
-5.1%
収益成長率
-5.1%
EPS成長率
| Pharmaceuticals 業界の成長 | 17.5% |
| 収益成長率 | 4.9% |
| 株主資本利益率 | 11.8% |
| ネット・マージン | 11.8% |
| 前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Calculating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Apr 14収支内訳
収支内訳
Aurobindo Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 297,184 | 35,214 | 41,633 | 0 |
| 31 Mar 24 | 290,019 | 31,730 | 40,434 | 0 |
| 31 Dec 23 | 278,947 | 27,705 | 38,823 | 0 |
| 30 Sep 23 | 269,500 | 23,254 | 38,143 | 0 |
| 30 Jun 23 | 254,700 | 19,777 | 37,278 | 0 |
| 31 Mar 23 | 248,554 | 19,275 | 36,560 | 0 |
| 31 Dec 22 | 241,918 | 19,977 | 36,478 | 0 |
| 30 Sep 22 | 237,869 | 21,112 | 35,950 | 0 |
| 30 Jun 22 | 239,894 | 23,987 | 35,854 | 0 |
| 31 Mar 22 | 234,555 | 26,482 | 35,751 | 0 |
| 31 Dec 21 | 236,476 | 28,676 | 35,746 | 0 |
| 30 Sep 21 | 240,103 | 52,109 | 35,865 | 0 |
| 30 Jun 21 | 245,518 | 53,217 | 36,395 | 0 |
| 31 Mar 21 | 247,746 | 53,348 | 36,576 | 0 |
| 31 Dec 20 | 249,316 | 53,831 | 36,591 | 0 |
| 30 Sep 20 | 244,617 | 31,421 | 35,761 | 0 |
| 30 Jun 20 | 235,787 | 29,757 | 34,414 | 0 |
| 31 Mar 20 | 230,985 | 28,451 | 33,333 | 0 |
| 31 Dec 19 | 222,323 | 25,666 | 32,224 | 0 |
| 30 Sep 19 | 216,070 | 25,733 | 30,744 | 0 |
| 30 Jun 19 | 207,579 | 25,449 | 29,226 | 0 |
| 31 Mar 19 | 195,636 | 23,647 | 27,389 | 0 |
| 31 Dec 18 | 183,834 | 23,078 | 25,632 | 0 |
| 30 Sep 18 | 174,246 | 21,906 | 24,541 | 0 |
| 30 Jun 18 | 171,091 | 23,603 | 23,473 | 0 |
| 31 Mar 18 | 164,630 | 24,232 | 22,414 | 0 |
| 31 Dec 17 | 159,381 | 24,271 | 20,903 | 0 |
| 30 Sep 17 | 154,903 | 24,107 | 19,953 | 0 |
| 30 Jun 17 | 148,279 | 22,352 | 19,032 | 0 |
| 31 Mar 17 | 149,334 | 23,017 | 18,451 | 0 |
| 31 Dec 16 | 151,565 | 22,809 | 17,799 | 0 |
| 30 Sep 16 | 147,559 | 22,466 | 17,359 | 0 |
| 30 Jun 16 | 143,446 | 20,945 | 16,823 | 0 |
| 31 Mar 16 | 138,162 | 20,251 | 16,019 | 0 |
| 31 Dec 15 | 133,249 | 18,230 | 28,438 | 894 |
| 30 Sep 15 | 129,956 | 16,724 | 27,775 | 894 |
| 30 Jun 15 | 125,433 | 15,928 | 26,938 | 894 |
| 31 Mar 15 | 121,340 | 15,758 | 13,548 | 0 |
| 31 Dec 14 | 112,825 | 16,738 | 17,756 | 624 |
| 30 Sep 14 | 102,756 | 17,069 | 16,210 | 624 |
| 30 Jun 14 | 93,109 | 15,697 | 14,800 | 624 |
| 31 Mar 14 | 81,002 | 11,729 | 13,273 | 624 |
| 31 Dec 13 | 73,736 | 7,797 | 12,261 | 423 |
| 30 Sep 13 | 67,900 | 4,540 | 11,795 | 423 |
質の高い収益: AUROPHARMAは 高品質の収益 を持っています。
利益率の向上: AUROPHARMAの現在の純利益率 (10.9%)は、昨年(7.8%)よりも高くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: AUROPHARMAの収益は過去 5 年間で年間4.6%減少しました。
成長の加速: AUROPHARMAの過去 1 年間の収益成長率 ( 64.6% ) は、5 年間の平均 ( 年間-4.6%を上回っています。
収益対業界: AUROPHARMAの過去 1 年間の収益成長率 ( 64.6% ) はPharmaceuticals業界18%を上回りました。
株主資本利益率
高いROE: AUROPHARMAの 自己資本利益率 ( 10.6% ) は 低い とみなされます。